Helminth Regulation of Immunity: A Three-pronged Approach to Treat Colitis

Inflammatory Bowel Diseases

Volumn 22, Issue 10, 2016, Pages 2499-2512

  Lopes, Fernando ^a   Matisz, Chelsea ^a   Reyes, José L ^a,b   Jijon, Humberto ^a,c   Al Darmaki, Ahmed ^c   Kaplan, Gilaad G ^a,c   McKay, Derek M ^a  

^a University of Calgary and Alberta Health Services   (Canada)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

cellular immunotherapy; helminth extract; IBD

Indexed keywords

CYSTATIN; INTERLEUKIN 10; PARASITE ANTIGEN; SYNTHETASE; TRANSFORMING GROWTH FACTOR BETA;

ACANTHOCHEILONEMA VITEAE; BRUGIA MALAYI; COLITIS; COLON FLORA; DENDRITIC CELL; ECHINOCOCCUS GRANULOSUS; HOST PARASITE INTERACTION; HUMAN; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOTHERAPY; MACROPHAGE; NONHUMAN; PARASITE IMMUNITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SCHISTOSOMA MANSONI; THERAPY WITH HELMINTHS; TRICHINELLA SPIRALIS; ADOPTIVE TRANSFER; ANIMAL; ANIMAL MODEL; HELMINTH; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; PARASITOLOGY;

ADOPTIVE TRANSFER; ANIMALS; COLITIS; DENDRITIC CELLS; HELMINTHS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; MODELS, ANIMAL; T-LYMPHOCYTES, REGULATORY;

EID: 84988575880     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000889     Document Type: Review

References (159)

1. Ciccarelli F, De Martinis M, Ginaldi L. An update on autoinflammatory diseases. Curr Med Chem. 2013;21:261-269
2. Debruyn JC, Soon IS, Hubbard J, et al. Nationwide temporal trends in incidence of hospitalization and surgical intestinal resection in pediatric inflammatory bowel diseases in the United States from 1997 to 2009. Inflamm Bowel Dis. 2013;19:2423-2432
3. Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058
4. Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014;7:6-19
5. Danese S, Rudzinski J, Brandt W, et al. Tralokinumab for moderate-tosevere UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut. 2015;64:243-249
6. Weinstock JV, Elliott DE. Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis. 2009;15:128-133
7. Steinfelder S, O'Regan NL, Hartmann S. Diplomatic assistance: can helminth-modulated macrophages act as treatment for inflammatory disease? PLoS Pathog. 2016;12:e1005480
8. Fleming JO. Helminth therapy and multiple sclerosis. Int J Parasitol. 2013;43:259-274
9. Reardon C, Sanchez A, Hogaboam CM, et al. Tapeworm infection reduces epithelial ion transport abnormalities in murine dextran sulfate sodium-induced colitis. Infect Immun. 2001;69:4417-4423
10. Summers RW, Elliott DE, Qadir K, et al. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2003;98:2034-2041
11. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380:1590-1605
12. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012; 380:1606-1619
13. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434
14. Liu TC, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. Ann Rev Pathol. 2016;23:127-148
15. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329-342
16. McGovern DP, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases. Gastroenterology. 2015;149:1163-1176
17. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-g, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261-1270
18. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol. 1995;101:428-435
19. Basu R, Hatton RD, Weaver CT. The Th17 family: flexibility follows function. Immunol Rev. 2013;252:89-103
20. Tosiek MJ, Fiette L, El Daker S, et al. IL-15-dependent balance between Foxp3 and RORgt expression impacts inflammatory bowel disease. Nat Commun. 2016;7:10888
21. Gross M, Salame TM, Jung S. Guardians of the gut-murine intestinal macrophages and dendritic cells. Front Immunol. 2015;6:254
22. Shouval DS, Biswas A, Goettel JA, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and antiinflammatory macrophage function. Immunity. 2014;40:706-719
23. Zigmond E, Bernshtein B, Friedlander G, et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity. 2014;40:720-733
24. Mann ER, Landy JD, Bernardo D, et al. Intestinal dendritic cells: their role in intestinal inflammation, manipulation by the gut microbiota and differences between mice and men. Immunol Lett. 2013;150:30-40
25. Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005;129:50-65
26. Mann ER, Bernardo D, Ng SC, et al. Human gut dendritic cells drive aberrant gut-specific T-cell responses in ulcerative colitis, characterized by increased IL-4 production and loss of IL-22 and IFNg. Inflamm Bowel Dis. 2014;20:2299-2307
27. Serafini N, Vosshenrich CA, Di Santo JP. Transcriptional regulation of innate lymphoid cell fate. Nat Rev Immunol. 2015;15:415-428
28. Bernink JH, Peters CP, Munneke M, et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol. 2013; 14:221-229
29. Sonnenberg GF, Monticelli LA, Alenghat T, et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science. 2012;336:1321-1325
30. McKay DM. The therapeutic helminth? Trends Parasitol. 2009;25:109-114
31. Desowitz M. New Guinea Tapeworms, and Jewish Grandmothers. chpt. 9: London: WW Norton &Company; 1981:179-205
32. Rook GA, Raison CL, Lowry CA. Microbiota, immunoregulatory old friends and psychiatric disorders. Ad Exp Med Biol. 2014;817:319-356
33. Kaplan GG. IBD: global variations in environmental risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2014;11:708-709
34. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299: 1259-1260
35. Haahtela T, Holgate S, Pawankar R, et al. The biodiversity hypothesis and allergic disease: world allergy organization position statement. World Allergy Org J. 2013;6:3
36. Donskow-Lysoniewska K, Majewski P, Brodaczewska K, et al. Heligmosmoides polygyrus fourth stages induce protection against DSSinduced colitis and change opioid expression in the intestine. Parasite Immunol. 2012;34:536-546
37. Elliott DE, Setiawan T, Metwali A, et al. Heligmosomoides polygyrus inhibits established colitis in IL-10-deficient mice. Eur J Immunol. 2004; 34:2690-2698
38. Elliott DE, Metwali A, Leung J, et al. Colonization with Heligmosomoides polygyrus suppresses mucosal IL-17 production. J Immunol. 2008;181:2414-2419
39. Hang L, Setiawan T, Blum AM, et al. Heligmosomoides polygyrus infection can inhibit colitis through direct interaction with innate immunity. J Immunol. 2010;185:3184-3189
40. Setiawan T, Metwali A, Blum AM, et al. Heligmosomoides polygyrus promotes regulatory T-cell cytokine production in the murine normal distal intestine. Infect Immun. 2007;75:4655-4663
41. Adisakwattana P, Nuamtanong S, Kusolsuk T, et al. Non-encapsulated Trichinella spp., T. papuae, diminishes severity of DSS-induced colitis in mice. Asian Pac J Allergy Immunol. 2013;31:106-114
42. Cho MK, Park MK, Kang SA, et al. Trichinella spiralis infection suppressed gut inflammation with CD4+CD25+Foxp3+ T cell recruitment. Kor J Parasitol. 2012;50:385-390
43. Elliott DE, Li J, Blum A, et al. Exposure to schistosome eggs protects mice from TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol. 2003;284:G385-G391
44. Bodammer P, Waitz G, Loebermann M, et al. Schistosoma mansoni infection but not egg antigen promotes recovery from colitis in outbred NMRI mice. Dig Dis Sci. 2011;56:70-78
45. Persaud R, Wang A, Reardon C, et al. Characterization of the immunoregulatory response to the tapeworm Hymenolepis diminuta in the nonpermissive mouse host. Internat J Parasitol. 2007;37:393-403
46. Hunter MM, Wang A, Hirota CL, et al. Neutralizing anti-IL-10 antibody blocks the protective effect of tapeworm infection in a murine model of chemically induced colitis. J Immunol. 2005;174:7368-7375
47. Ledesma-Soto Y, Callejas BE, Terrazas CA, et al. Extraintestinal helminth infection limits pathology and pro-inflammatory cytokine expression during DSS-induced ulcerative colitis: a role for alternatively activated macrophages and prostaglandins. Biomed Res Int. 2015;2015: 563425
48. Reynolds LA, Finlay BB, Maizels RM. Cohabitation in the intestine: interactions among helminth parasites, bacterial microbiota, and host immunity. J Immunol. 2015;195:4059-4066
49. Smith P, Mangan NE, Walsh CM, et al. Infection with a helminth parasite prevents experimental colitis via a macrophage-mediated mechanism. J Immunol. 2007;178:4557-4566
50. Ince MN, Elliott DE, Setiawan T, et al. Role of T cell TGF-b signaling in intestinal cytokine responses and helminthic immune modulation. Eur J Immunol. 2009;39:1870-1878
51. Metwali A, Setiawan T, Blum AM, et al. Induction of CD8+ regulatory T cells in the intestine by Heligmosomoides polygyrus infection. Am J Physiol Gastrointest Liver Physiol. 2006;291:G253-G259
52. Reyes JL, Wang A, Fernando MR, et al. Splenic B cells from Hymenolepis diminuta-infected mice ameliorate colitis independent of T cells and via cooperation with macrophages. J Immunol. 2015;194:364-378
53. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:754-759
54. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352-1355
55. Fantini MC, Becker C, Tubbe I, et al. Transforming growth factorb induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut. 2006;55:671-680
56. Sedda S, Marafini I, Dinallo V, et al. The TGF-b/Smad system in IBD pathogenesis. Inflamm Bowel Dis. 2015;21:2921-2925
57. Reyes JL, Fernando MR, Lopes F, et al. IL-22 restrains tapewormmediated protection against experimental colitis via regulation of IL-25 expression. PLoS Pathog. 2016;12:e1005481
58. Howitt MR, Lavoie S, Michaud M, et al. Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut. Science. 2016;351: 1329-1333
59. Gerbe F, Sidot E, Smyth DJ, et al. Intestinal epithelial tuft cells initiate type 2 mucosal immunity to helminth parasites. Nature. 2016;529:226-230
60. von Moltke J, Ji M, Liang HE, et al. Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit. Nature. 2016;529:221-225
61. Goldberg R, Prescott N, Lord GM, et al. The unusual suspects-innate lymphoid cells as novel therapeutic targets in IBD. Nat Rev Gastroenterol Hepatol. 2015;12:271-283
62. Besnard AG, Guabiraba R, Niedbala W, et al. IL-33-mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells. PLoS Pathog. 2015;11:e1004607
63. Lopes F, Reyes JL, Wang A, et al. Enteric epithelial cells support growth of Hymenolepis diminuta in vitro and trigger TH2-promoting events in a species-specific manner. Internat J Parasitol. 2015;45:691-696
64. Taylor BC, Zaph C, Troy AE, et al. TSLP regulates intestinal immunity and inflammation in mouse models of helminth infection and colitis. J Exp Med. 2009;206:655-667
65. Leung G, Wang A, Fernando M, et al. Bone marrow-derived alternatively activated macrophages reduce colitis without promoting fibrosis: participation of IL-10. Am J Physiol Gastrointest Liver Physiol. 2013; 304:G781-G792
66. Hunter MM, Wang A, Parhar KS, et al. In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology. 2010;138:1395-1405
67. Weisser SB, Kozicky LK, Brugger HK, et al. Arginase activity in alternatively activated macrophages protects PI3Kp110d deficient mice from dextran sodium sulfate induced intestinal inflammation. Eur J Immunol. 2014;44:3353-3367
68. DeGruttola AK, Low D, Mizoguchi A, et al. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016;22:1137-1150
69. Hayes KS, Bancroft AJ, Goldrick M, et al. Exploitation of the intestinal microflora by the parasitic nematode Trichuris Muris. Science. 2010;328: 1391-1394
70. Turner JE, Stockinger B, Helmby H. IL-22 mediates goblet cell hyperplasia and worm expulsion in intestinal helminth infection. PLoS Pathog. 2013;9:e1003698
71. Walk ST, Blum AM, Ewing SA, et al. Alteration of the murine gut microbiota during infection with the parasitic helminth Heligmosomoides Polygyrus. Inflamm Bowel Dis. 2010;16:1841-1849
72. Fox JG, Beck P, Dangler CA, et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy. Nat Med. 2000;6:536-542
73. Osborne LC, Monticelli LA, Nice TJ, et al. Coinfection. Virus-helminth coinfection reveals a microbiota-independent mechanism of immunomodulation. Science. 2014;345:578-582
74. Broadhurst MJ, Ardeshir A, Kanwar B, et al. Therapeutic helminth infection of macaques with idiopathic chronic diarrhea alters the inflammatory signature and mucosal microbiota of the colon. PLoS Pathog. 2012;8:e1003000
75. Zaiss MM, Rapin A, Lebon L, et al. The intestinal microbiota contributes to the ability of helminths to modulate allergic inflammation. Immunity. 2015;43:998-1010
76. Ramanan D, Bowcutt R, Lee SC, et al. Helminth infection promotes colonization resistance via type 2 immunity. Science. 2016;352:608-612
77. McKay DM. Not all parasites are protective. Parasite Immunol. 2015;37: 324-332
78. Monin L, Griffiths KL, Lam WY, et al. Helminth-induced arginase-1 exacerbates lung inflammation and disease severity in tuberculosis. J Clin Invest. 2015;125:4699-4713
79. Chen CC, Louie S, McCormick B, et al. Concurrent infection with an intestinal helminth parasite impairs host resistance to enteric Citrobacter rodentium and enhances Citrobacter-induced colitis in mice. Infect Immun. 2005;73:5468-5481
80. Bhardwaj EK, Else KJ, Rogan MT, et al. Increased susceptibility to Trichuris muris infection and exacerbation of colitis in Mdr1a2/2 mice. World J Gastroenterol. 2014;20:1797-1806
81. Hunter MM, Wang A, McKay DM. Helminth infection enhances disease in a murine TH2 model of colitis. Gastroenterology. 2007;132:1320-1330
82. Summers RW, Urban J, Elliott D, et al. Th2 Conditioning by Trichuris suis appears safe and effective in modifying the mucosal immune response in inflammatory bowel Disease. Gastroenterology. 1999;116: A828 (G3592) (abstract)
83. Sandborn WJ, Elliott DE, Weinstock J, et al. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther. 2013;38:255-263
84. Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 2005;128:825-832
85. Lukes J, Kuchta R, Scholz T, et al. Self- infections with parasites: reinterpretations for the present. Trends Parasitol. 2014;30:377-385
86. Broadhurst MJ, Leung JM, Kashyap V, et al. IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient. Sci Translat Med. 2010;2:60ra88
87. Croese J, Giacomin P, Navarro S, et al. Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease. J Allergy Clin Immunol. 2015;135:508-516
88. Croese J, O'Neil J, Masson J, et al. A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors. Gut. 2006; 55:136-137
89. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine US. CgIBMNLoM. Identifier: NCT01576471 Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo (TRUST-i). Available from: https://clinicaltrialsgov/ct2/show/NCT01576471. April 10, 2012
90. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine US. CgIBMNLoM. Identifier: NCT01279577 Trichuris Suis Ova (TSO) Suspension versus Placebo in Active Crohn's Disease (TRUST-2). Available from: https://clinicaltrialsgov/ct2/show/NCT01279577. January 18, 2011
91. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine US. CgIBMNLoM. Identifier: NCT01953354-trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis. Available from: https:// clinicaltrialsgov/ct2/show/NCT01953354. 2013 September 24
92. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine US. CgIBMNLoM. Identifier: NCT01433471 Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy with Trichuris Suis Ova (MUCUS). Available from: https://clinicaltrialsgov/ct2/show/NCT01433471. September 6, 2011
93. Weinstock JV, Elliott DE. Translatability of helminth therapy in inflammatory bowel diseases. Int J Parasitol. 2013;43:245-251
94. Garg SK, Croft AM, Bager P. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Cochrane Database Syst Rev. 2014;1:Cd009400
95. McSorley HJ, Hewitson JP, Maizels RM. Immunomodulation by helminth parasites: defining mechanisms and mediators. Int J Parasitol. 2013;43:301-310
96. Harnett W. Secretory products of helminth parasites as immunomodulators. Mol Biochem Parasitol. 2014;195:130-136
97. Johnston MJ, Wang A, Catarino ME, et al. Extracts of the rat tapeworm, Hymenolepis diminuta, suppress macrophage activation in vitro and alleviate chemically induced colitis in mice. Infect Immun. 2010;78: 1364-1375
98. Ziegler T, Rausch S, Steinfelder S, et al. A novel regulatory macrophage induced by a helminth molecule instructs IL-10 in CD4+ T cells and protects against mucosal inflammation. J Immunol. 2015;194:1555-1564
99. Ruyssers NE, De Winter BY, De Man JG, et al. Therapeutic potential of helminth soluble proteins in TNBS-induced colitis in mice. Inflamm Bowel Dis. 2009;15:491-500
100. Cancado GG, Fiuza JA, de Paiva NC, et al. Hookworm products ameliorate dextran sodium sulfate-induced colitis in BALB/c mice. Inflamm Bowel Dis. 2011;17:2275-2286
101. Kron MA, Metwali A, Vodanovic-Jankovic S, et al. Nematode asparaginyl-tRNA synthetase resolves intestinal inflammation in mice with T-cell transfer colitis. Clin Vaccin Immunol. 2013;20:276-281
102. Motomura Y, Wang H, Deng Y, et al. Helminth antigen-based strategy to ameliorate inflammation in an experimental model of colitis. Clin Exp Immunol. 2009;155:88-95
103. Yang X, Yang Y, Wang Y, et al. Excretory/secretory products from Trichinella spiralis adult worms ameliorate DSS-induced colitis in mice. PLoS One. 2014;9:e96454
104. Du L, Tang H, Ma Z, et al. The protective effect of the recombinant 53-kDa protein of Trichinella spiralis on experimental colitis in mice. Dig Dis Sci. 2011;56:2810-2817
105. Jang SW, Cho MK, Park MK, et al. Parasitic helminth cystatin inhibits DSS-induced intestinal inflammation via IL-10+F4/80+ macrophage recruitment. Kor J Parasitol. 2011;49:245-254
106. Ruyssers NE, De Winter BY, De Man JG, et al. Schistosoma mansoni proteins attenuate gastrointestinal motility disturbances during experimental colitis in mice. World J Gastroenterol. 2010;16:703-712
107. Heylen M, Ruyssers NE, De Man JG, et al. Worm proteins of Schistosoma mansoni reduce the severity of experimental chronic colitis in mice by suppressing colonic pro-inflammatory immune responses. PLoS One. 2014;9:e110002
108. Hasby EA, Hasby Saad MA, Shohieb Z, et al. FoxP3+ T regulatory cells and immunomodulation after Schistosoma mansoni egg antigen immunization in experimental model of inflammatory bowel disease. Cell Immunol. 2015;295:67-76
109. Soufli I, Toumi R, Rafa H, et al. Crude extract of hydatid laminated layer from Echinococcus granulosus cyst attenuates mucosal intestinal damage and inflammatory responses in dextran sulfate sodium induced colitis in mice. J Inflamm. 2015;12:19
110. Smith P, Fallon RE, Mangan NE, et al. Schistosoma mansoni secretes a chemokine binding protein with anti-inflammatory activity. J Exp Med. 2005;202:1319-1325
111. Wilson MS, Mentink-Kane MM, Pesce JT, et al. Immunopathology of schistosomiasis. Immunol Cell Biol. 2007;85:148-154
112. Heylen M, Ruyssers NE, Nullens S, et al. Treatment with egg antigens of Schistosoma mansoni ameliorates experimental colitis in mice through a colonic T-cell-dependent mechanism. Inflamm Bowel Dis. 2015;21:48-59
113. Loke P, MacDonald AS, Robb A, et al. Alternatively activated macrophages induced by nematode infection inhibit proliferation via cell-tocell contact. Eur J Immunol. 2000;30:2669-2678
114. Falcone FH, Loke P, Zang X, et al. A Brugia malayi homolog of macrophage migration inhibitory factor reveals an important link between macrophages and eosinophil recruitment during nematode infection. J Immunol. 2001;167:5348-5354
115. Hewitson JP, Ruckerl D, Harcus Y, et al. The secreted triose phosphate isomerase of Brugia malayi is required to sustain microfilaria production in vivo. Plos Pathog. 2014;10:e1003930
116. Sofronic-Milosavljevic L, Ilic N, Pinelli E, et al. Secretory Products of Trichinella spiralis muscle larvae and immunomodulation: implication for autoimmune diseases, allergies, and malignancies. J Immunol Res. 2015;2015:523875
117. Siracusano A, Delunardo F, Teggi A, et al. Cystic echinococcosis: aspects of immune response, immunopathogenesis and immune evasion from the human host. Endo Met Imm Disord Drug Targets. 2012;12: 16-23
118. Diaz A, Casaravilla C, Allen JE, et al. Understanding the laminated layer of larval Echinococcus II: immunology. Trends Parasitol. 2011; 27:264-273
119. Schnoeller C, Rausch S, Pillai S, et al. A helminth immunomodulator reduces allergic and inflammatory responses by induction of IL-10-producing macrophages. J Immunol. 2008;180:4265-4272
120. Terrazas LI, Montero D, Terrazas CA, et al. Role of the programmed death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis. Internat J Parasitol. 2005; 35:1349-1358
121. Elliott DE, Weinstock JV. Where are we on worms? Curr Opin Gastroenterol. 2012;28:551-556
122. Johnston MJ, MacDonald JA, McKay DM. Parasitic helminths: a pharmacopeia of anti-inflammatory molecules. Parasitology. 2009;136: 125-147
123. Pineda MA, Eason RJ, Harnett MM, et al. From the worm to the pill, the parasitic worm product ES-62 raises new horizons in the treatment of rheumatoid arthritis. Lupus. 2015;24:400-411
124. Tsai IJ, Zarowiecki M, Holroyd N, et al. The genomes of four tapeworm species reveal adaptations to parasitism. Nature. 2013;496:57-63
125. Britton C, Winter AD, Marks ND, et al. Application of small RNA technology for improved control of parasitic helminths. Vet Parasitol. 2015;212:47-53
126. Mangano VD, Modiano D. Host genetics and parasitic infections. Clin Microbiol Infect. 2014;20:1265-1275
127. Esser-Bieren J, Volpe B, Sutherland DB, et al. Immune antibodies and helminth products drive CXCR2-dependent macrophagemyofibroblast crosstalk to promote intestinal repair. PLoS Pathog. 2015;11:e1004778
128. Vos AC, Wildenberg ME, Duijvestein M, et al. Anti-tumor necrosis factor-A antibodies induce regulatory macrophages in an Fc regiondependent manner. Gastroenterology. 2011;140:221-230
129. Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology. 2005;128:552-563
130. Burt RK, Craig RM, Milanetti F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn's disease: long-term follow-up. Blood. 2010;116:6123-6132
131. Cassinotti A, Annaloro C, Ardizzone S, et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut. 2008;57:211-217
132. Hasselblatt P, Drognitz K, Potthoff K, et al. Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther. 2012;36: 725-735
133. Hawkey CJ, Allez M, Clark MM, et al. Autologous hematopoetic stem cell transplantation for refractory Crohn's disease: a randomized cinical trial. JAMA. 2015;314:2524-2534
134. Onken JE, Norata GD, Hanson J, et al. Successful out-patient treatment of refractory Crohn's Disease using adult mesenchymal stem cells. Am Coll Gastroenterol Annu Meet. 2006;NV: Abstract 121
135. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrowderived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut. 2010;59:1662-1669
136. Forbes GM, Sturm MJ, Leong RW, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol. 2014;12:64-71
137. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut. 2011;60:788-798
138. Garcia-Olmo D, Garcia-Arranz M, Herreros D, et al. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416-1423
139. De la Portilla F, Alba F, Garcia-Olmo D, et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28:313-323
140. Garcia-Olmo D, Guadalajara H, Rubio-Perez I, et al. Recurrent anal fistulae: limited surgery supported by stem cells. World J Gastroenterol. 2015;21:3330-3336
141. Geem D, Harusato A, Flannigan K, et al. Harnessing regulatory T cells for the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1409-1418
142. Desreumaux P, Foussat A, Allez M, et al. Safety and efficacy of antigenspecific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology. 2012;143:1207-1217
143. Blum AM, Hang L, Setiawan T, et al. Heligmosomoides polygyrus bakeri induces tolerogenic dendritic cells that block colitis and prevent antigen-specific gut T cell responses. J Immunol. 2012;189:2512-2520
144. Leung G, Petri B, Reyes JL, et al. Cryopreserved IL-4-treated macrophages attenuate murine colitis in an integrin b7-dependent manner. Mol Med. 2015;21:924-936
145. Hang L, Blum AM, Setiawan T, et al. Heligmosomoides polygyrus bakeri infection activates colonic Foxp3+ T cells enhancing their capacity to prevent colitis. J Immunol. 2013;191:1927-1934
146. Matisz CE, Leung G, Reyes JL, et al. Adoptive transfer of helminth antigen-pulsed dendritic cells protects against the development of experimental colitis in mice. Eur J Immunol. 2015;45:3126-3139
147. Conde P, Rodriguez M, van der Touw W, et al. DC-SIGN+ macrophages control the induction of transplantation tolerance. Immunity. 2015;42: 1143-1158
148. Donnelly S, O'Neill SM, Sekiya M, et al. Thioredoxin peroxidase secreted by Fasciola hepatica induces the alternative activation of macrophages. Infect Immun. 2005;73:166-173
149. Adams PN, Aldridge A, Vukman KV, et al. Fasciola hepatica tegumental antigens indirectly induce an M2 macrophage-like phenotype in vivo. Parasite Immunol. 2014;36:531-539
150. Figueroa-Santiago O, Espino AM. Fasciola hepatica fatty acid binding protein induces the alternative activation of human macrophages. Infect Immun. 2014;82:5005-5012
151. Morse MA, Niedzwiecki D, Marshall JL, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg. 2013; 258:879-886
152. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58
153. Iclozan C, Antonia S, Chiappori A, et al. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013;62:909-918
154. Tel J, Aarntzen EH, Baba T, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 2013;73:1063-1075
155. Carranza F, Falcon CR, Nunez N, et al. Helminth antigens enable CpGactivated dendritic cells to inhibit the symptoms of collagen-induced arthritis through Foxp3+ regulatory T cells. PLoS One. 2012;7:e40356
156. Delgado M, Gonzalez-Rey E, Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol. 2005;175:7311-7324
157. Foligne B, Zoumpopoulou G, Dewulf J, et al. A key role of dendritic cells in probiotic functionality. PLoS One. 2007;2:e313
158. Mododecky N, Soon IS, Rabi D, et al. Increasing incidence of inflammatory bowel disease with time and among regions based on systematic review. Gastroenterology. 2012;142:46-54
159. Frolkis A, Dieleman LA, Barkeam HW, et al. Environment and the inflammatory bowel diseases. Can J Gastroenterol Hepatol. 2013;27: 18-24